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Abstract The joint European Society of Cardiology and Eu-
ropean Association of Cardio-Thoracic Surgery (ESC/
EACTS) guidelines on myocardial revascularization collect
and summarize the evidence regarding decision-making, di-
agnostics, and therapeutics in various clinical scenarios of
coronary artery disease, including elective, urgent, and emer-
gency settings. The 2014 document updates and extends the
effort started in 2010, year of the first edition of these guide-
lines. Importantly, this latest edition provides a systematic
review of all randomized clinical trials performed since
1980, comparing different strategies of myocardial revascular-
ization, including coronary artery bypass graft (CABG), bal-
loon angioplasty, percutaneous coronary intervention (PCI)
with bare-metal stents (BMS) and first- and second-
generation drug-eluting stents (DES). This review aims to
highlight the most relevant novelties introduced by the 2014
edition of the ESC/EACTS myocardial revascularization
guidelines as compared with the previous edition and to de-
scribe similarities and differences with the American socie-
ties’ guidelines.
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Introduction
The most recent edition of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Sur-
gery (EACTS) joint guidelines on myocardial revasculariza-
tion celebrates the 50th anniversary of the first coronary artery
bypass graft (CABG) procedure [1, 2]. The first percutaneous
coronary revascularization procedure was performed only
13 years thereafter, in 1977. Since their first introduction, re-
vascularization techniques gained expertise and clinical rele-
vance worldwide, becoming one of the most commonly per-
formed interventions in modern medicine. The ESC joint
guidelines inform European and non-European practitioners
since the early 2000s and represent the endeavor of dozens of
clinical and research professionals in the field of cardiovascular
medicine. The 2014 edition of the ESC/EACTS revasculariza-
tion guidelines provides a concise and updated summary of the
evidence surrounding the value of revascularization in various
clinical scenarios, including elective, urgent, and emergency
settings. Unique to this edition, they provide a systematic re-
view of all randomized clinical trials performed since 1980,
comparing different strategies of myocardial revascularization,
including CABG, balloon angioplasty, percutaneous coronary
intervention (PCI) with bare-metal stents (BMS) and first- and
second-generation drug-eluting stents (DES).
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The following perspective paper is intended to highlight
the most relevant novelties in the field of revascularization
introduced in these guidelines, as compared with the previous
2010 edition [3]. In addition, similarities and differences with
respect to the American societies’ guidelines on myocardial
revascularization are discussed whenever proper [4–9].
The Heart Team: from Inception to Mainstream
The 2010 edition of the ESC guidelines introduced and
strongly empowered the concept of the Heart Team. This has
been a great achievement whereby all relevant cardiac special-
ties and heart care providers are brought together to choose the
best revascularization modality for each single patient. Cur-
rent guidelines further extend the importance of the Heart
Team discussion, by inciting the development of shared insti-
tutional protocols, in order to better select the patients that
deserve a multidisciplinary evaluation, saving time, resources,
and delays of urgent procedures, especially in centers without
on-site surgery. American guidelines also advocate the insti-
tution of the Heart Team, indicating the need for multidisci-
plinary discussion in patients with left main coronary artery
disease (CAD) or complex multivessel CAD.
Applying Risk Scores in Practice
Aiming at achieving the best revascularization modality for
each individual patient, the 2014 ESC/EACTS revasculariza-
tion guidelines have updated and expanded the risk score sec-
tion. The Society of Thoracic Surgeons (STS) score is recog-
nized as the appropriate, recommended tool to stratify surgical
risk during CABG, whereas the role of the EuroScore has
been reconsidered and its use is no longer indicated, based
on the concern that it overestimates the surgical risk
(Table 1). However, the newly introduced EuroScore II
overcomes this limitation, and its use should be preferred over
the first iteration of this surgical risk score.
The Synergy Between Percutaneous Coronary Intervention
with TAXUS and Cardiac Surgery (SYNTAX) score, introduced
in the previous edition, is now recommended for the risk strati-
fication of patients who undergo revascularization (CABG vs.
PCI). The more recent SYNTAX II score has been introduced in
this guidelines edition for the very first time (Table 1). The latter
is a combination of anatomical and clinical factors that were
found to be superior to the conventional SYNTAX score in guid-
ing decision-making between CABG and PCI [10].
Among the aforementioned scores, STS and SYNTAX are
also mentioned in the American guidelines as reasonable tools
to guide the decision-making of the revascularization modality.
Revascularization of the Left Main Coronary Artery
There is increasing evidence that both CABG and PCI may
provide effective treatment for selected patients with left main
CAD, especially those with an overall low to intermediate an-
atomical complexity. A prespecified analysis of the SYNTAX
trial evaluated a subgroup of patients with predominant distal
left main disease [11]. Despite its limited statistical power, this
study showed that CABG and PCI had a comparable rate of the
primary endpoint—a composite of death, myocardial infarc-
tion, stroke, and repeat revascularization—in the low and inter-
mediate SYNTAX tertile (SYNTAX score ≤22 and SYNTAX
score 23–32). In contrast, it observed a numerical increase of
deaths and a significant increase of repeat revascularizations in
the PCI group with the highest SYNTAX tertile (SYNTAX
>32). In keeping with this, the PRECOMBAT trial showed
comparable outcomes at 1 and 2 years in patients with LM
disease treated with CABG or PCI [12].
Based on these data, the indication for PCI of left main
CAD with low anatomical complexity (SYNTAX score ≤22)
has been upgraded and now equated to CABG, whereas in
anatomies with intermediate (SYNTAX score 23–32) com-
plexity, PCI should be considered, but CABG remains the
preferred revascularization modality (Table 2).
Similar to the 2010 edition, the most recent revasculariza-
tion guidelines reiterate the contraindication to the elective
treatment of left main CAD with PCI, in case of high anatom-
ical complexity (SYNTAX >32) in patients who have an ac-
ceptable surgical risk (Table 2). Properly powered trials eval-
uating the outcomes of the new-generation DES vs. CABG
are still lacking. The EXCEL trial is expected to provide im-
portant insights on this matter.
At variance from the European document, the American
societies’ guidelines recommend CABG for the treatment of
left main CAD and suggest PCI as an alternative in patients
with an increased surgical risk and an amenable anatomy [4, 6,
9] (Table 2).
Table 1 Comparison among guidelines indications for risk scoring
ESC GL 2014 ESC GL 2010 American societies’ GL
CABG PCI CABG PCI CABG and PCI
STS score I B – I B – • IIa Ba
EuroScore III B III C I B IIb B –
EuroScore II IIa B IIb C – – –
SYNTAX I B I B III B IIa B • IIa Ba
SYNTAX II IIa B IIa B – – –
ESC European Society of Cardiology, GL guidelines
a From the 2011 ACCF/AHA/SCAI PCI Guideline [4]: this document
specifies that calculation of STS and SYNTAX is reasonable in patients
with unprotected left main and complex CAD
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Revascularization of the Proximal Left Anterior
Descending Artery
PCI indication was upgraded for the treatment of the proximal
left anterior descending artery (LAD) disease (Table 3). In this
regard, one study comparing PCI with DES and CABG in
patients with isolated proximal LAD disease demonstrated
similar outcomes over a 10-year follow-up [13]. Similarly,
no survival benefit with CABG vs. PCI was observed for the
treatment of two-vessel disease including proximal LAD. Ac-
cordingly, PCI is now equally recommended as CABG for the
treatment of proximal LAD alone as well as in the context of a
two-vessel disease. This recommendation slightly diverges
from the American document, which considers CABG supe-
rior for the treatment of two-vessel disease including the prox-
imal LAD [6, 9].
Revascularization for Three-Vessel Coronary Artery
Disease
At variance with previous guidelines, PCI is now equally rec-
ommended as CABG for the treatment of three-vessel disease
with a low anatomical complexity (SYNTAX score≤22)
[14–16], whereas in more complex anatomies (SYNTAX
score >22), PCI is still contraindicated (Table 4).
These recommendations are largely based on the results of
the 5-year follow-up of the SYNTAX trial. CABG showed
better outcomes in the overall three-vessel disease population,
whereas PCI demonstrated to be a reasonable alternative in
those with a low SYNTAX score ≤22, although at the price of
an increased risk of repeat revascularization [16]. The risk of
stroke in this population has been shown to be lower after PCI
as compared to CABG. The SYNTAX trial tested the effect of
TAXUS stent implantation, a first-generation DES. Given the
overwhelming evidence showing superior outcomes when
newer generation DES are compared to paclitaxel-eluting
stent in patients undergoing coronary stent implantation, it
remains likely that the use of newer generation DES may
further improve the efficacy and safety of PCI when compared
to CABG in this high-risk population. This hypothesis re-
quires validation in prospective clinical trials.
Revascularization in Patients with Comorbidities
The 2014 edition largely focuses on revascularization modal-
ities in patients with various comorbidities, especially diabetes
mellitus and chronic kidney disease.
Table 2 Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD and left main coronary artery disease with suitable
anatomy and low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GLc
CABG PCI CABG PCI PCI
SYNTAX score ≤22 I B I B I A IIa/b Ba • IIa B—if low risk of PCI complications and significantly increased
surgical risk (e.g., STS ≥5 %)
SYNTAX score 23–32 I B IIa B I A IIb Bb • IIb B—if low to intermediate risk of PCI complications and increased
surgical risk (e.g., STS >2 %)
SYNTAX score >32 I B III B I A III B • III B—if unfavorable anatomy for PCI and good candidates for CABG
GL guidelines
a Indication IIa B for left main lesion at ostium/shaft. Indication IIb B for left main lesion at distal bifurcation
b Indication for left main disease associated to two- or three-vessel disease and a SYNTAX score ≤32
c Indication to improve survival with revascularization as compared to medical therapy
Table 3 Recommendation for
the type of revascularization
(CABG or PCI) in patients with
SCAD and proximal left anterior
descending coronary artery
disease with suitable anatomy and
low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GLa
CABG PCI CABG PCI
One-vessel disease I A I A I A IIa B • IIa B for CABG with LIMA
• IIb B for PCI
Two-vessel disease I B I C I A IIa B • I B for CABG
• IIb B for PCI
GL guidelines
a Indication to improve survival with revascularization as compared to medical therapy
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CABG is strongly recommended over PCI for patients with
diabetes and multivessel disease, provided surgical risk is ac-
ceptable. In cases where a percutaneous treatment is indicated,
new-generation DES should be preferred over bare-metal
stents [15, 17]. In keeping with this, American guidelines also
indicate CABG as the treatment of choice in patients with
diabetes and multivessel disease [9].
These recommendations are mainly based on the results of
the FREEDOM trial [15]; this study randomized diabetic pa-
tients with multivessel disease to CABG or PCI+DES and
found a significantly higher rate of the primary endpoint—a
composite of death, myocardial infarction, and stroke—in the
PCI group. Moreover, death and myocardial infarction oc-
curred more frequently in the PCI group, whereas stroke rate
was higher after CABG. Similar results are provided by a
recent meta-analysis that confirmed a survival benefit of
CABG over PCI in diabetic patients with multivessel disease,
irrespectively the use of DES or BMS [17].
As in diabetic patients, new guidelines recommend
new-generation DES over BMS in patients with chronic
kidney disease (CKD). In patients with CKD and
multivessel disease, CABG is still the treatment of choice,
with off-pump CABG that may be preferred over the on-
pump approach [18].
The lack of properly powered randomized trials comparing
different revascularization modalities is notable in this setting.
In patients at risk of contrast-induced acute kidney injury, the
use of short-term, high-dose statin therapy should be consid-
ered [19].
Antiplatelet Therapy and Revascularization
New guidelines no longer indicate to pretreat with clopidogrel
all patients scheduled for a diagnostic coronary angiogram
(Supplementary Table 1); indeed, pretreatment did not outper-
form no-pretreatment option in a meta-analysis of 37,814 pa-
tients, which included both prospective controlled studies and
retrospective registry data [20]. Differently, it remains reason-
able to pretreat patients with known coronary anatomy sched-
uled for PCI. Pretreatment may still be considered in cases
where the probability of CAD is high and the anticipated need
for urgent CABG unlikely.
The indications for dual antiplatelet therapy (DAPT) dura-
tion have been updated (Table 5). In patients with spontaneous
coronary artery dissection (SCAD) receiving a DES, 6-month
DAPT is now recommended. A shortened DAPT duration
may be considered in case of high bleeding risk. This indica-
tion was extrapolated from several trials comparing standard
or prolonged DAPT regimens with shorter courses, which
eventually failed to demonstrate a benefit from a prolonged
DAPT, but rather observed an increased risk of bleeding after
a longer therapy [21, 22].
If the individual ischemic risk is high and bleeding risk is
low, DAPT may be prolonged beyond 6 months. American
guidelines (GL) recommend at least 12 months of therapy in
patients with SCAD treated with DES, unless at high bleeding
risk (Supplementary Table 1).
The novel P2Y12 inhibitors, prasugrel or ticagrelor, are rec-
ommended as first-line treatment during acute coronary syn-
drome (ACS), whereas clopidogrel should be used only when
prasugrel and ticagrelor are not available (Supplementary
Table 2 and 3). American guidelines are less prescriptive
and state that it is reasonable to prefer ticagrelor over
clopidogrel, provided ischemic risk is high and an early inva-
sive strategy is planned, whereas they state that prasugrel
should be preferred over clopidogrel if the bleeding risk is
low [8].
Importantly, after the presentation of the ACCOAST
trial, the European GL now contraindicate the pretreatment
with prasugrel in patients with non-ST-segment elevation-
ACS (NSTE-ACS) and unknown coronary anatomy, given
the increased risk of major bleeding and the lack of is-
chemic benefit [23]. Notably, the administration of P2Y12
inhibitors before catheterization in ST segment elevation
myocardial infarction (STEMI) is recommended, and ide-
ally, they should be administered at the time of the first
medical contact. This recommendation is in keeping with
American guidelines and is supported by a small random-
ized study [24], two observational studies [25, 26], and
one meta-analysis [20] showing a reduction of death and
MACE without increase of bleeding, in STEMI patients
pretreated with clopidogrel.
Table 4 Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD and three-vessel coronary artery disease with
suitable anatomy and low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GL
CABG PCI CABG PCI
SYNTAX score ≤22 I A I B I A IIa B • IIa B—it is reasonable to choose CABG over PCI in patients with complex
three-vessel disease (e.g., SYNTAX >22) who are good candidates for CABGSYNTAX score 23–32 I A III B I A III A
SYNTAX score >32 I A III B I A III A
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Anticoagulant Therapy and Revascularization
The anticoagulation section has also been revised with some
novelties regarding the management of bivalirudin and use of
novel oral anticoagulants (NOAC).
In the previous edition of the European guidelines as well
as in Americans’ [7], bivalirudin had a first-class indication as
recommended anticoagulant during PCI in STEMI compared
to heparin plus glycoprotein IIb/IIIa inhibitors (GPI) (Supple-
mentary Table 3). However, the recently published HEAT
PPCI trial [27] did not show a reduction of bleeding in patients
treated with bivalirudin as compared to heparin alone. Ac-
cordingly, the current document gives bivalirudin a second-
class indication as anticoagulant in the setting of STEMI as
compared to heparin without GPI. While this new indication
has been largely interpreted as downgrading, it should be em-
phasized that previous guidelines set a recommendation of
bivalirudin instead of unfractionated heparin (UFH) plus rou-
tine use of glycoprotein IIb/IIIa inhibitors, whereas the more
recent availability of comparative effectiveness data of
bivalirudin versus UFH alone has made possible to provide
new recommendations of bivalirudin as contrasted to UFH
without routine use of glycoprotein IIb/IIIa inhibitors.
In the NSTE-ACS setting, bivalirudin administered during
the PCI and prolonged for up to 4 h thereafter has a class IA
indication as an alternative to UFH+GPI and is recommended
whenever available (Supplementary Table 2). This indication is
mainly driven by the results of the ACUITYand ISAR-REACT
4 trials where bivalirudin compared to UFH+GPI showed a
similar efficacy and a better bleeding profile [28, 29]. It has to
be highlighted that most of the evidence in this setting comes
from trials testing bivalirudin versus UFH+GPI, a combination
that is no longer routinely applied; thus, confirmation of
bivalirudin benefit in properly powered trials is still needed [30].
In elective patients instead, bivalirudin is recommended in
case of heparin-induced thrombocytopenia (Supplementary
Table 1).
In addition, a prolonged infusion of bivalirudin should now
be considered for up to 4 h after PCI, based on the concern of
an increased risk of acute stent thrombosis.
With respect to NOACS, these guidelines also mention the
possibility of adding a third agent, namely, rivaroxaban, on
top of the standard DAPT with aspirin and clopidogrel for
ACS patients treated with PCI in patients at low bleeding risk.
This is based on the recent ATLAS-ACS2 trial that observed a
mortality benefit from a triple therapy consisting of ASA,
clopidogrel, and low-dose rivaroxaban (i.e., 2.5 twice daily)
in patients recently treated for ACS [31]. However, this was at
an expense of an increase of severe bleeding, and no data
currently exists on the value of rivaroxaban when tested in
patients taking the new P2Y12 inhibitors.
The lack of formal guidance with respect to DAPT duration
in patients requiring long-term oral anticoagulation has now
been overcome with this edition of the guidelines. Also in this
setting, new-generation DES should be preferred over BMS,
provided that the bleeding risk is low (HAS BLED ≤2).
In patients with SCAD with absolute indication to
anticoagulation and low bleeding risk (HAS BLED ≤2), the
duration of the triple therapy—consisting of aspirin,
clopidogrel, and a (N)OAC—should be of at least 1 month
and ideally continued up to 12 months, whereas in patients
presenting ACS, triple therapy should be considered for 6 to
12 months, irrespective of the stent used. Importantly, for pa-
tients at high bleeding risk (HAS BLED>2), the duration of
triple therapy should be of 1 month irrespective the presenta-
tion (i.e., SCAD or ACS) and the type of stent used.
Recommendations on New-Generation Drug-Eluting
Stents
At variance with the previous document, which listed several
relative limitations to the use of DES, in the current edition,
second-generation drug-eluting stents receive an unrestricted
indication of use (Table 6). To support this, a network meta-
analysis recently published byWindecker et al. included more
than 100 studies comparing revascularization and medical
therapy in patients with stable coronary artery disease [32].
This meta-analysis showed a survival benefit for CABG as
compared to medical treatment, in keeping with previous data.
In addition, new-generation DES, but not balloon angioplasty,
BMS, or first-generation DES, showed a survival improve-
ment compared to medical therapy. This is the first report that
demonstrates a reduction of mortality in SCAD with percuta-
neous revascularization. A possible biological explanation for
the survival benefit of these new stents could be related to the
lower risk of myocardial infarction and stent thrombosis. This
is consistent with other recent studies that showed a dramatic
improvement in cardiac outcomes, including cardiac survival,
myocardial infarction, and stent thrombosis with cobalt-
chromium everolimus-eluting stents (new-generation de-
vices), compared with both first-generation DES and bare-
metal stents [33, 32, 34].
According to this evidence, new guidelines recommend
new-generation DES as default in all clinical conditions and
lesion subsets. In addition, the previous concerns associated
with early DAPT cessation are not confirmed by recent data,
and new-generation DES are recommended over BMS also in
patients who may require earlier discontinuation of antiplate-
let therapy. American guidelines profoundly diverge from the
current ESC position and list several, strong contraindication
to DES use as the inability, or the unproven ability, to comply
or tolerate a prolonged DAPT (Table 6). It is worth mention-
ing that American guidelines on percutaneous coronary inter-
vention date back to 2011, so it is possible that these differ-
ences will be in part leveled with updated editions.
216 J. of Cardiovasc. Trans. Res. (2015) 8:211–220
Conclusions and Future Perspectives
The 2014 edition of the ESC/EACTS guidelines implements
important novelties including the unrestricted indication to
new-generation DES, the modulation of DAPT duration ac-
cording to clinical presentation, and the new indications for
the treatment of left main and three-vessel CAD. The value of
bioresorbable polymer or no-polymer DES overmore conven-
tional durable polymer DES remains under evaluation, and
whether this more sophisticated technology will translate into
improved patient outcomes remains unsettled. The use of bio-
resorbable vascular scaffolds, instead of permanent metallic
DES, while highly promising for restoring physiological ves-
sel motion long-term after intervention remains also a matter
for ongoing research. The recent DAPT and PEGASUS trials
explored the effectiveness of a long-term treatment with a
P2Y12 inhibitor, clopidogrel/prasugrel for the first, ticagrelor
for the latter, showing ischemic benefit for reductions of pa-
t i en t and dev ice -o r i en t ed non- fa t a l endpo in t s ,
counterbalanced by higher bleeding rates [35, 36]. The opti-
mal DAPT type and duration, which maximize the benefits in
terms of ischemic protection and minimize the risks in terms
of bleeding, will be most likely based on the individual pa-
tient’s risk profile. It is probable that in the near future, strat-
egies based on weighting patients risk by the use of clinical
(i.e., risk scores), biochemical (i.e., circulating biomarkers), or
genetic-based tools (i.e., gene polymorphisms) will help phy-
sicians to better individualize this treatment.
The MATRIX program is the first large multicenter study
showing the superiority of the radial as compared to femoral
access, for the reduction of a net clinical benefit endpoint, driv-
en by lower major bleeding and mortality rates [30, 37–41].
Future recommendations will most likely further upgrade the
use of radial over femoral route for ACS patients undergoing
invasive management, which will have implications in terms of
training programs as well as health care quality assessment.
The decision to revascularize a given lesion or vessel in the
near future will likely depend even more on functional param-
eters. Some techniques have already demonstrated solid re-
sults (i.e., fractional flow reserve—FFR) whereas some more
recent potentially simplified iterations look promising (i.e.,
instantaneous wave-free ratio—IFR). The results of future
studies evaluating the incremental value of a routine function-
al evaluation and imaging-based stent optimization algorithm
may further optimize outcomes and patient selection in revas-
cularization procedures. The recent COSIRA study reported
the efficacy of a coronary sinus reducer to relieve symptoms in
patients with refractory angina not amenable for revasculari-
zation. This device may serve the growing proportion of pa-
tients that remains symptomatic despite maximal antianginal
therapy [42]. However, even if the concept of a mechanical
treatment of refractory angina is intriguing, more informative
clinical studies are needed to confirm the role of such device in
clinical practice.
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